Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase 1b, Crossover Study to Evaluate the Pharmacokinetics and Safety of a Subcutaneous Belantamab (BCMAb) Formulation With rHuPH20 Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

NCT07742527 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07742527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07742527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase 1b, Crossover Study to Evaluate the Pharmacokinetics and Safety of a Subcutaneous Belantamab (BCMAb) Formulation With rHuPH20 Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 16, 2026
Completion date
March 18, 2030
Enrollment
22 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma